Yep, not the news we were hoping for. But not bad news either. Most people who really knew their stats waivered around 50/50 on the first but were unanimous on a 2nd read out being a likely approval. We were never going to get the stats today. This is a blind trial to MSB. Only the DSMB sees the stats unblind, before people start panicking.
Hold or buy if it falls. Unlike the ODAC meeting this stock didn't rally ahead of the meeting (probably because of the silly stock movement preceding ODAC approval) so probably will not fall that much. Shorters selling ahead of a likely end of month 2nd reading will not fair well come October.
Ann: DSMB Recommends Continuation of Phase 3 COVID-19 Trial, page-41
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
-0.025(2.22%) |
Mkt cap ! $1.261B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.09 | $4.434M | 3.989M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 25 | 327828 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 18310 | 5 |
View Market Depth
| Last trade - 12.43pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |